Nothing said here yet.
to join the conversation.
| Wilterding MarkChief Financial Officer | Sell | 7,765 | $54.0K | Wed, Sep 2 |
| Kurtz Ronald M MDChief Medical Officer | Sell | 5,100 | $35.5K | Wed, Sep 2 |
| Goldshleger IlyaChief Operating Officer | Sell | 2,041 | $14.2K | Wed, Sep 2 |
| Weinberg EricSee remarks | Sell | 2,041 | $14.2K | Wed, Sep 2 |
RxSight (RXST) has upside potential if it executes salesforce expansion and utilization-growth initi
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts.
Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery.
Alcon partnership revenue offsets 19% product sales decline from competitive pressure.
RxSight Inc (RXST) navigates a challenging quarter with a 19% product sales drop while securing a transformative $200 million Alcon collaboration and planning to double its U.S. sales team.
RxSight (RXST) delivered earnings and revenue surprises of +47.62% and +2.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RxSight’s latest valuation work has taken the modelled fair value from US$9.93 to US$8.43, which points to a refreshed view of what the stock may be worth under updated assumptions.
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.